Stock CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 21:00:02 12/12/2024 GMT 		5-day change 1st Jan Change
194.27 USD +0.37% Intraday chart for Charles River Laboratories International, Inc. +1.43% -17.82%
12-04 Charles River Laboratories International, Inc. Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference, Dec-04-2024 10:00 AM
11-26 Goldman Sachs Adjusts Price Target on Charles River Laboratories International to $220 From $240, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Charles River Introduces Global Biotech Incubator Program
12-05
 BU
Charles River Laboratories to Present at Evercore ISI Investor Conference
12-02
 BU
'Serious risks': Researchers join push against importing monkeys for drug testing
11-13
 AQ
Charles River Laboratories to Present at UBS and Jefferies Conferences
11-11
 BU
Charles River Laboratories International : CRL 3Q24 Financial Reconciliations & Appendix
11-06
 PU
Charles River Laboratories International : Q3 2024 Earnings Presentation
11-06
 PU
Charles River Laboratories International : ANNOUNCES THIRD QUARTER 2024 RESULTS Form 8 K
11-06
 PU
Charles River Laboratories International : CRL 3Q24 Earnings Release (11 06 24)
11-06
 PU
Charles River: Q3 Earnings Snapshot
11-06
 AQ
Charles River Laboratories Announces Third-Quarter 2024 Results
11-06
 BU
Ottawa urged to halt imports of endangered monkeys for drug testing, amid U.S. probe
10-30
 AQ
Charles River Launches New Retrogenix® Non-Human Protein Library
10-17
 BU
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call
10-16
 BU
Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica to Advance the Discovery of Novel Drugs for Neurological Disease
10-03
 AQ
Charles River Provides Translational Expertise at Neuroscience 2024
10-03
 BU
Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease
10-02
 BU
Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research
09-17
 BU
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
09-04
 BU
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
09-03
 BU
Charles River Laboratories International : CRL 2Q24 Financial Reconciliations (08 07 24)
08-07
 PU
Charles River: Q2 Earnings Snapshot
08-07
 AQ
Charles River Laboratories Announces Second-Quarter 2024 Results
08-07
 BU
Charles River Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy Development
07-30
 BU
Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
07-24
 BU
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
07-16
 BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRL Stock
  4. News Charles River Laboratories International, Inc.
  5. Press Releases
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition